U.K., Pfizer Cite AstraZeneca Options
LONDON ( The Deal ) -- U.K. Business Secretary Vince Cable said Tuesday he was working to ensure job and investment commitments made by Pfizer
Cable was speaking before a committee of House of Commons lawmakers, who earlier in the day had grilled Pfizer CEO Ian Read about his plans for the unwilling target and heard evidence from AstraZeneca CEO Pascal Soriot.
The offer, which could culminate in the U.K.'s largest ever takeover, has become a lightning rod for concerns that Britain is handing over too much of its industrial base to foreign acquirers. Cable said his government faced a "dilemma" in contemplating such bids.
"We are an open economy. We benefit from it. We don't want to do anything that will disrupt that but there are wider national interests and we want to do our best to protect them," he said.
He said the long gestation period of any bid -- assuming Pfizer opts to proceed by a May 26 Takeover Panel deadline -- would allow plenty of scope for government intervention after the summer break. This would involve secondary rather than primary legislation, he said, and ministers would also work with the Takeover Panel to examine untested powers to ensure bidders' pre-takeover commitments towards their targets are legally binding.
"Our judgment is the existence of the parliamentary recess doesn't impede our freedom to make any action we might make," he said. "If the assurances are not satisfactory then there is the option of legislative remedies."
"There are legal and financial mechanisms I would rather not describe in detail but we are certainly considering a range of ways" to ensure Pfizer sticks to its pre-takeover promises, he added.
He also said the Conservative-Liberal Democrat cabinet was united over how to approach the bid. Last week, Prime Minister David Cameron confirmed he was open to Cable's idea of expanding the government's limited "public interest" powers to examine takeover offers, though Cable conceded on Tuesday that any such intervention would be "quite tricky."
"We work as team. My colleagues have made it very clear that just like me they want the options kept open ... both in terms of securing assurances and potentially of an intervention."
He also said Pfizer commitments made earlier this month in an open letter to David Cameron were "just a starting point."
Read pledged in the letter to put 20% of the combined company's R&D workforce in the U.K. for five years. Giving evidence to lawmakers earlier in the day he would not specify numbers. But he confirmed that the enlarged entity's R&D budget, now $12 billion combined, would fall overall and jobs would go.